Xolair, co-developed and co-promoted by San Francisco-based Genentech and East Hanover, N.J.-based Novartis, is the first medicine approved to treat CIU since H1-antihistamines, according to the news release.
In 2003, Xolair was approved to treat persistent allergic asthma.
More Articles on FDA Approvals:
FDA Approves Neuraceq for Brain Imaging
FDA Approves Implantable Device for Certain Type of Hearing Loss
FDA Approves Apixaban for New Use
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.